Szilard V.
- Country
- Hungary
- Department
- NA
Research Overview
- Efficacy and Safety of MET097 in Adults with Overweight or Obesity: A Phase 3, Randomized, Placebo-Controlled Trial
- Phase 3 Randomized, Placebo‑Controlled Trial Assessing Efficacy and Safety of MET097, a Long‑Acting GLP‑1 Receptor Agonist, in Overweight/Obese Adults with Type 2 Diabetes
- Phase 3 Randomized Double-Blind Placebo-Controlled Study of KAI-9531 in Adults With Obesity or Overweight and Diabetes
Data & Insights
Has run more than one trial at 794 of 1480 partner sites.
Specializations
Cardiovascular Disease Management
This investigator specializes in treating atherosclerotic cardiovascular disease (ASCVD) and atrial fibrillation, with particular focus on innovative therapeutic approaches for prevention of major cardiovascular events.
- Coronary heart disease interventions
- Stroke prevention strategies
- Arterial revascularization procedures
Metabolic Disorders
Expertise in treating complex metabolic conditions including type 2 diabetes, severe hypertriglyceridemia, and mixed dyslipidemia. The investigator works with advanced therapeutic agents for metabolic regulation.
- Diabetes management
- Lipid disorders
- Obesity treatment
Renal and Cardiovascular Comorbidities
Focuses on treating patients with chronic kidney disease (CKD) complicated by hypertension and heart failure risk. Specializes in integrated therapeutic approaches for complex cardiovascular-renal conditions.
- CKD progression management
- Heart failure prevention
- Blood pressure control
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.